Granules India news & stock notes

16 Sep 2026

Granules India received the balance Rs 1,093 crore from its promoter group, making 2.49 crore convertible warrants eligible for conversion.

With Rs 365.63 crore paid upfront, the issue is fully funded and the company expects to turn net cash surplus on a consolidated basis. The promoter had sold shares for about Rs 1,500 crore four days earlier.

12 Sep 2026

Granules India's promoter sold 1.72 crore shares for about Rs 1,500 crore, taking the promoter group to 31.08 percent from 38.02 percent.

The proceeds fund the second tranche of the company's own preferential issue, so the stake cut puts money into Granules rather than taking it out. Capital Group, Kotak Life and ChrysCapital bought.

06 Jul 2026

Granules India secured sole first-to-file ANDA status for sodium oxybate extended-release for oral suspension.

First-to-file gives a period of US marketing exclusivity, and this is a high-value, hard-to-make product. It lifts the US specialty pipeline.

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.